IL-37 (human) ELISA Kit
AG-45A-0041YEK
Product group Assays
Overview
- SupplierAdipoGen Life Sciences
- Product NameIL-37 (human) ELISA Kit
- Delivery Days Customer10
- ApplicationsELISA
- Assay Detection Range0.016 to 1ng/ml
- Assay Sensitivity10pg/ml
- Assay SpecificityDetects human IL-37 (monomeric and dimeric forms). Does not cross-react with human IL-33, IL-38, IL-6, IL-23, IL-24 or mouse IL-33 and IL-38.
- CertificationResearch Use Only
- Scientific DescriptionELISA Assay. Detects human IL-37. Does not cross-react with human IL-33, human IL-6, human IL-23, human IL-24 or mouse IL-33. Colorimetric assay. Sample Types: Plasma, Serum. Range: 0.016 to 1ng/ml. Sensitivity: 10pg/ml. IL-37 (IL-1F7; IL-1H4) is an IL-1 family member that is expressed only in certain types of human organs and cells such as heart, thymus, testis, kidney, mononuclear cells (PBMCs) and dendritic cells. IL-37 is an inhibitor of innate immunity with anti-inflammatory properties. It binds to the interleukin-18 receptor (IL-18R) and its co-receptor SIGIRR. IL-37 is secreted as a full-length and as a processed form starting from amino acid Val46. It plays an important role as a link between innate and adaptive immunity and acts as an inhibitor of autoimmune diseases and tumor growth. IL-37 also inhibited Lipopolysaccharide (LPS)-induced immunological reaction and LPS-induced osteoclast formation and bone resorption. - IL-37 (IL-1F7; IL-1H4) is an IL-1 family member that is expressed only in certain types of human organs and cells such as heart, thymus, testis, kidney, mononuclear cells (PBMCs) and dendritic cells. IL-37 is an inhibitor of innate immunity with anti-inflammatory properties. It binds to the interleukin-18 receptor (IL-18R) and its co-receptor SIGIRR. IL-37 is secreted as a full-length and as a processed form starting from amino acid Val46. It plays an important role as a link between innate and adaptive immunity and acts as an inhibitor of autoimmune diseases and tumor growth. IL-37 also inhibited Lipopolysaccharide (LPS)-induced immunological reaction and LPS-induced osteoclast formation and bone resorption. A recent study indicates that IL-37 protein forms a head-to-head homodimer and this structure limits its bioactivity. Variants with mutations converting the cytokine into a monomeric form are 13 fold more active than the dimeric IL-37.
- Storage Instruction2°C to 8°C
- UNSPSC41116158
References
- Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment: C. Li, et al.; J. Interferon Cytokine Res. 33, 612 (2013)
- Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with guillain-barré syndrome: C. Li, et al.; Mediators Inflamm. 2013, 639712 (2013)
- IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity: L. Ye, et al.; J. Transl. Med. 12, 69 (2014)
- Plasma Levels of IL-37 and Correlation with TNF-alpha, IL-17A, and Disease Activity during DMARD Treatment of Rheumatoid Arthritis: P.-W. Zhao, et al.; PLOS One 9, e95346 (2014)
- Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis: P. Italiani, et al.; J. Neuroinflamm. 11, 94 (2014)
- Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome: Q. Ji, et al.; Mediat. Inflamm. 2014, ID165742 (2014)
- Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity: B. Chen, et al.; J. Transl. Med. 13, 36 (2015)
- Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer: G. Ge, et al.; J. Exp. Clin. Cancer Res. 35, 13 (2016)
- Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus: J. Godsell, et al.; Sci. Reports6, 34604 (2016)